Vivoryon Therapeutics AG (GB:0R3M) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Vivoryon Therapeutics N.V. is set to present its findings on Varoglutamstat, a potential new treatment for Diabetic Kidney Disease, at ASN Kidney Week 2024. The clinical-stage biotechnology company is exploring Varoglutamstat’s ability to increase glomerular filtration in the elderly without proteinuria. Vivoryon, known for its work on small molecule medicines, continues to expand its pipeline with treatments for Alzheimer’s, kidney diseases, cancer, and more.
For further insights into GB:0R3M stock, check out TipRanks’ Stock Analysis page.